INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 438m ago
HOUSE PTR38m ago
SEC 13F38m ago
ROBINHOOD CHAIN37m ago
SEC FORM 4/Open-market saleVerified data

Smith Nicholas Conrad sold ANRO

PRESIDENT AND CFO · Alto Neuroscience, Inc. · Common Stock

Side
SELL
Value
$2.95M
Shares
110.8K
Price
$26.58
Executed
Sep 29, 2026
Disclosed
Oct 1, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 29 executedOct 1, 2026 disclosed

ANRO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
42/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+22 / 25

    $2.9M reported value · 82.2% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ANRO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    55.0K sh
    		Oct 2, 2026Oct 5, 2026
    traded Oct 2, 2026
    		+3dSEC FORM 4

    Evidence

    20
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$128K
    55.0K sh
    		Oct 2, 2026Oct 5, 2026
    traded Oct 2, 2026
    		+3dSEC FORM 4

    Evidence

    13
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    24.1K sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    21
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    56.5K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    54.4K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    17
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Open-market sale
    		SELL$24K
    886 sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    20
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$57K
    24.1K sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    24
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$133K
    56.5K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    24
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$128K
    54.4K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    31
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Open-market sale
    		SELL$597K
    23.2K sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    24
    EA
    Etkin AmitDirector, PRESIDENT AND CEO
    ANROAlto Neuroscience, Inc.
    Gift
    		G—
    400.0K sh
    		May 14, 2026May 15, 2026
    traded May 14, 2026
    		+1dSEC FORM 4

    Evidence

    9
    YG
    York GwillDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    11.0K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MH
    Manji HusseiniDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    11.0K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CN
    Cox Christopher NixonDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    11.0K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SR
    Sanchez RamiroDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    11.0K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SA
    Savitz AdamCHIEF MEDICAL OFFICER
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    124.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HC
    Hanley Jr. Michael ConickCHIEF OPERATING OFFICER
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    131.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SC
    Smith Nicholas ConradCHIEF FINANCIAL OFFICER & CBO
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    200.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    EA
    Etkin AmitDirector, PRESIDENT AND CEO
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    306.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MH
    Manji HusseiniDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A$50K
    4,228 sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002009130-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 29, 2026
    Published
    Oct 1, 2026
    Ingested by INSIDER
    Nov 5, 02:13 UTC
    Last re-read
    Nov 5, 02:13 UTC

    Extracted facts

    Filer
    Smith Nicholas Conrad
    Role
    PRESIDENT AND CFO
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Alto Neuroscience, Inc.
    Ticker
    ANRO
    Shares
    110.8K
    Price per share
    $26.58
    Value
    $2,946,150
    Execution date (reported)
    Sep 29, 2026
    Owned after transaction
    24.1K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 110.8K
    • Price: $26.5826

    = $2,946,150

    What this establishes

    Smith Nicholas Conrad filed this Form 4 reporting a open-market sale of ANRO on Sep 29, 2026. It became public on Oct 1, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    PRESIDENT AND CFO
    Smith Nicholas Conradcik:0002009130
    Issuer
    Alto Neuroscience, Inc.cik:0001999480

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.